GCP ClinPlus Secures Series B Funding!

We are proud to announce the successful completion of our Series B financing, led by Taikun Fund, one of the largest life science investment funds in China, with participation from multiple well-known investors — a strong vote of confidence in our long-term growth potential, global strategy, and professional service capabilities.

For 22 years, GCP ClinPlus has been dedicated to advancing clinical research, supporting 2,200+ clinical projects and helping 210+ products secure approvals across China, the U.S., and Europe. We've built industry-leading strengths in biostatistics, data management, and CGT clinical development, with a proven track record:

80+ CGT clinical studies across small nucleic acids, CAR-T, RNA, stem cell, and gene therapy — including China's first approved stem cell therapy.

500+ oncology trials and extensive work in autoimmune, ophthalmology, CNS, rare diseases, and metabolic disorders.

Trusted partnerships with top hospitals, experienced PIs, and global biotech and pharma companies.

This funding will further strengthen our CGT and biostatistics capabilities, accelerate global expansion, and enhance our ability to deliver fast, high-quality, cost-efficient clinical trials that connect China's executional excellence with global standards.

A big thank you to our investors, clients, and partners for your continued trust and collaboration. Together, we'll keep pushing the boundaries to bring innovative therapies to patients faster.